ILK and ovarian carcinoma: We also observed that transfection of ILK-siRNA reduced the invasive potential of cisplatin-resistant ovarian cancer cells, which is in agreement with previous studies showing that ILK activity modulates the pro-metastatic behavior of ovarian cancer [17].